Duplications in the G3 domain or switch II region in HRAS identified in patients with Costello syndrome.
Costello syndrome
G3 domain
HRAS
intragenic duplication
switch II region
Journal
Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
27
09
2021
received:
29
04
2021
accepted:
30
09
2021
pubmed:
8
10
2021
medline:
1
4
2022
entrez:
7
10
2021
Statut:
ppublish
Résumé
Costello syndrome (CS) is an autosomal-dominant disorder characterized by distinctive facial features, hypertrophic cardiomyopathy, skeletal abnormalities, intellectual disability, and predisposition to cancers. Germline variants in HRAS have been identified in patients with CS. Intragenic HRAS duplications have been reported in three patients with a milder phenotype of CS. In this study, we identified two known HRAS variants, p.(Glu63_Asp69dup), p.(Glu62_Arg68dup), and one novel HRAS variant, p.(Ile55_Asp57dup), in patients with CS, including a patient with craniosynostosis. These intragenic duplications are located in the G3 domain and the switch II region. Cells expressing cDNA with these three intragenic duplications showed an increase in ELK-1 transactivation. Injection of wild-type or mutant HRAS mRNAs with intragenic duplications in zebrafish embryos showed significant elongation of the yolk at 11 h postfertilization, which was improved by MEK inhibitor treatment, and a variety of developmental abnormalities at 3 days post fertilization was observed. These results indicate that small in-frame duplications affecting the G3 domain and switch II region of HRAS increase the activation of the ERK pathway, resulting in developmental abnormalities in zebrafish or patients with CS.
Substances chimiques
HRAS protein, human
EC 3.6.5.2
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3-15Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Addissie, Y. A., Kotecha, U., Hart, R. A., Martinez, A. F., Kruszka, P., & Muenke, M. (2015). Craniosynostosis and Noonan syndrome with KRAS mutations: Expanding the phenotype with a case report and review of the literature. American Journal of Medical Genetics, Part A, 167A(11), 2657-2663. https://doi.org/10.1002/ajmg.a.37259
Anastasaki, C., Estep, A. L., Marais, R., Rauen, K. A., & Patton, E. E. (2009). Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Human Molecular Genetics, 18(14), 2543-2554. https://doi.org/10.1093/hmg/ddp186
Aoki, K., Kumagai, Y., Sakurai, A., Komatsu, N., Fujita, Y., Shionyu, C., & Matsuda, M. (2013). Stochastic ERK activation induced by noise and cell-to-cell propagation regulates cell density-dependent proliferation. Molecular Cell, 52(4), 529-540. https://doi.org/10.1016/j.molcel.2013.09.015
Aoki, Y., Niihori, T., Banjo, T., Okamoto, N., Mizuno, S., Kurosawa, K., Ogata, T., Takada, F., Yano, M., Ando, T., Hoshika, T., Barnett, C., Ohashi, H., Kawame, H., Hasegawa, T., Okutani, T., Nagashima, T., Hasegawa, S., Funayama, R., … Matsubara, Y. (2013). Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. American Journal of Human Genetics, 93(1), 173-180. https://doi.org/10.1016/j.ajhg.2013.05.021
Aoki, Y., Niihori, T., Inoue, S., & Matsubara, Y. (2016). Recent advances in RASopathies. Journal of Human Genetics, 61(1), 33-39. https://doi.org/10.1038/jhg.2015.114
Aoki, Y., Niihori, T., Kawame, H., Kurosawa, K., Ohashi, H., Tanaka, Y., Filocamo, M., Kato, K., Suzuki, Y., Kure, S., & Matsubara, Y. (2005). Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nature Genetics, 37(10), 1038-1040. https://doi.org/10.1038/ng1641
Bertola, D., Yamamoto, G., Buscarilli, M., Jorge, A., Passos-Bueno, M. R., & Kim, C. (2017). The recurrent PPP1CB mutation p.Pro49Arg in an additional Noonan-like syndrome individual: Broadening the clinical phenotype. American Journal of Medical Genetics, Part A, 173(3), 824-828. https://doi.org/10.1002/ajmg.a.38070
Bonetti, M., Paardekooper Overman, J., Tessadori, F., Noel, E., Bakkers, J., & den Hertog, J. (2014). Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish. Development, 141(9), 1961-1970. https://doi.org/10.1242/dev.106310
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991). The GTPase superfamily: Conserved structure and molecular mechanism. Nature, 349(6305), 117-127. https://doi.org/10.1038/349117a0
Davis, R. J. (2000). Signal transduction by the JNK Group of MAP kinases. Cell, 103(2), 239-252. https://doi.org/10.1016/s0092-8674(00)00116-1
Eijkelenboom, A., van Schaik, F., van Es, R. M., Ten Broek, R. W., Rinne, T., van der Vleuten, C., Flucke, U., Ligtenberg, M., & Rehmann, H. (2019). Functional characterisation of a novel class of in-frame insertion variants of KRAS and HRAS. Scientific Reports, 9(1), 8239. https://doi.org/10.1038/s41598-019-44584-7
Gremer, L., De Luca, A., Merbitz-Zahradnik, T., Dallapiccola, B., Morlot, S., Tartaglia, M., Kutsche, K., Ahmadian, M. R., & Rosenberger, G. (2010). Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation. Human Molecular Genetics, 19(5), 790-802. https://doi.org/10.1093/hmg/ddp548
Gremer, L., Merbitz-Zahradnik, T., Dvorsky, R., Cirstea, I. C., Kratz, C. P., Zenker, M., Wittinghofer, A., & Ahmadian, M. R. (2011). Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Human Mutation, 32(1), 33-43. https://doi.org/10.1002/humu.21377
Gripp, K. W., Baker, L., Robbins, K. M., Stabley, D. L., Bellus, G. A., Kolbe, V., Nauth, T., & Rosenberger, G. (2020). The novel duplication HRAS c.186_206dup p.(Glu62_Arg68dup): Clinical and functional aspects. European Journal of Human Genetics, 28(11), 1548-1554. https://doi.org/10.1038/s41431-020-0662-4
Gripp, K. W., Morse, L. A., Axelrad, M., Chatfield, K. C., Chidekel, A., Dobyns, W., Doyle, D., Kerr, B., Lin, A. E., Schwartz, D. D., Sibbles, B. J., Siegel, D., Shankar, S. P., Stevenson, D. A., Thacker, M. M., Weaver, K. N., White, S. M., & Rauen, K. A. (2019). Costello syndrome: Clinical phenotype, genotype, and management guidelines. American Journal of Medical Genetics, Part A, 179(9), 1725-1744. https://doi.org/10.1002/ajmg.a.61270
Jopling, C., van Geemen, D., & den Hertog, J. (2007). Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects. PLOS Genetics, 3(12), e225. https://doi.org/10.1371/journal.pgen.0030225
Kratz, C. P., Zampino, G., Kriek, M., Kant, S. G., Leoni, C., Pantaleoni, F., Oudesluys-Murphy, A. M., Di Rocco, C., Kloska, S. P., Tartaglia, M., & Zenker, M. (2009). Craniosynostosis in patients with Noonan syndrome caused by germline KRAS mutations. American Journal of Medical Genetics, Part A, 149A(5), 1036-1040. https://doi.org/10.1002/ajmg.a.32786
Lorenz, S., Lissewski, C., Simsek-Kiper, P. O., Alanay, Y., Boduroglu, K., Zenker, M., & Rosenberger, G. (2013). Functional analysis of a duplication (p.E63_D69dup) in the switch II region of HRAS: New aspects of the molecular pathogenesis underlying Costello syndrome. Human Molecular Genetics, 22(8), 1643-1653. https://doi.org/10.1093/hmg/ddt014
Madeira, F., Park, Y. M., Lee, J., Buso, N., Gur, T., Madhusoodanan, N., Basutkar, P., Tivey, A., Potter, S. C., Finn, R. D., & Lopez, R. (2019). The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Research, 47(W1), W636-W641. https://doi.org/10.1093/nar/gkz268
Malumbres, M., & Barbacid, M. (2003). RAS oncogenes: The first 30 years. Nature Reviews: Cancer, 3(6), 459-465. https://doi.org/10.1038/nrc1097
McDonald, B. S., Pigors, M., Kelsell, D. P., O'Toole, E. A., Burkitt-Wright, E., Kerr, B., & Batta, K. (2018). Noonan syndrome with multiple lentigines and associated craniosynostosis. Clinical and Experimental Dermatology, 43(3), 357-359. https://doi.org/10.1111/ced.13329
Milburn, M. V., Tong, L., deVos, A. M., Brunger, A., Yamaizumi, Z., Nishimura, S., & Kim, S. H. (1990). Molecular switch for signal transduction: Structural differences between active and inactive forms of protooncogenic ras proteins. Science, 247(4945), 939-945. https://doi.org/10.1126/science.2406906
Niihori, T., Aoki, Y., Okamoto, N., Kurosawa, K., Ohashi, H., Mizuno, S., Kawame, H., Inazawa, J., Ohura, T., Arai, H., Nabatame, S., Kikuchi, K., Kuroki, Y., Miura, M., Tanaka, T., Ohtake, A., Omori, I., Ihara, K., Mabe, H., … Matsubara, Y. (2011). HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome. Journal of Human Genetics, 56(10), 707-715. https://doi.org/10.1038/jhg.2011.85
Niihori, T., Nagai, K., Fujita, A., Ohashi, H., Okamoto, N., Okada, S., Harada, A., Kihara, H., Arbogast, T., Funayama, R., Shirota, M., Nakayama, K., Abe, T., Inoue, S. I., Tsai, I. C., Matsumoto, N., Davis, E. E., Katsanis, N., & Aoki, Y. (2019). Germline-activating RRAS2 mutations cause Noonan syndrome. American Journal of Human Genetics, 104(6), 1233-1240. https://doi.org/10.1016/j.ajhg.2019.04.014
Pantaleoni, F., Lev, D., Cirstea, I. C., Motta, M., Lepri, F. R., Bottero, L., Cecchetti, S., Linger, I., Paolacci, S., Flex, E., Novelli, A., Carè, A., Ahmadian, M. R., Stellacci, E., & Tartaglia, M. (2017). Aberrant HRAS transcript processing underlies a distinctive phenotype within the RASopathy clinical spectrum. Human Mutation, 38(7), 798-804. https://doi.org/10.1002/humu.23224
Pathak, E. (2017). Analysis of correlated mutations in Ras G-domain. Bioinformation, 13(6), 174-178. https://doi.org/10.6026/97320630013174
Patterson, V. L., & Burdine, R. D. (2020). Swimming toward solutions: Using fish and frogs as models for understanding RASopathies. Birth Defects Research, 112(10), 749-765. https://doi.org/10.1002/bdr2.1707
Rauen, K. A. (2007). HRAS and the Costello syndrome. Clinical Genetics, 71(2), 101-108. https://doi.org/10.1111/j.1399-0004.2007.00743.x
Rodriguez, F., Ponce, D., Berward, F. J., Lopetegui, B., Cassorla, F., & Aracena, M. (2019). RAF1 variant in a patient with Noonan syndrome with multiple lentigines and craniosynostosis. American Journal of Medical Genetics, Part A, 179(8), 1598-1602. https://doi.org/10.1002/ajmg.a.61203
Runtuwene, V., van Eekelen, M., Overvoorde, J., Rehmann, H., Yntema, H. G., Nillesen, W. M., van Haeringen, A., van der Burgt, I., Burgering, B., & den Hertog, J. (2011). Noonan syndrome gain-of-function mutations in NRAS cause zebrafish gastrulation defects. Disease Models & Mechanisms, 4(3), 393-399. https://doi.org/10.1242/dmm.007112
Sprang, S. R. (1997). G protein mechanisms: Insights from structural analysis. Annual Review of Biochemistry, 66, 639-678. https://doi.org/10.1146/annurev.biochem.66.1.639
Suzuki-Muromoto, S., Miyabayashi, T., Nagai, K., Yamamura-Suzuki, S., Anzai, M., Takezawa, Y., Sato, R., Okubo, Y., Endo, W., Inui, T., Togashi, N., Kikuchi, A., Niihori, T., Aoki, Y., Kure, S., & Haginoya, K. (2019). Leucine-485 deletion variant of BRAF may exhibit the severe end of the clinical spectrum of CFC syndrome. Journal of Human Genetics, 64(5), 499-504. https://doi.org/10.1038/s10038-019-0579-3
Takenouchi, T., Sakamoto, Y., Miwa, T., Torii, C., Kosaki, R., Kishi, K., Takahashi, T., & Kosaki, K. (2014). Severe craniosynostosis with Noonan syndrome phenotype associated with SHOC2 mutation: Clinical evidence of crosslink between FGFR and RAS signaling pathways. American Journal of Medical Genetics, Part A, 164A(11), 2869-2872. https://doi.org/10.1002/ajmg.a.36705
Thumar, J., Shahbazian, D., Aziz, S. A., Jilaveanu, L. B., & Kluger, H. M. (2014). MEK targeting in N-RAS mutated metastatic melanoma. Molecular Cancer, 13, 45. https://doi.org/10.1186/1476-4598-13-45
Tidyman, W. E., & Rauen, K. A. (2009). The RASopathies: Developmental syndromes of Ras/MAPK pathway dysregulation. Current Opinion in Genetics and Development, 19(3), 230-236. https://doi.org/10.1016/j.gde.2009.04.001
Ueda, K., Yaoita, M., Niihori, T., Aoki, Y., & Okamoto, N. (2017). Craniosynostosis in patients with RASopathies: Accumulating clinical evidence for expanding the phenotype. American Journal of Medical Genetics, Part A, 173(9), 2346-2352. https://doi.org/10.1002/ajmg.a.38337
Vetter, I. R., & Wittinghofer, A. (2001). The guanine nucleotide-binding switch in three dimensions. Science, 294(5545), 1299-1304. https://doi.org/10.1126/science.1062023
Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F. T., de Beer, T., Rempfer, C., Bordoli, L., Lepore, R., & Schwede, T. (2018). SWISS-MODEL: Homology modelling of protein structures and complexes. Nucleic Acids Research, 46(W1), W296-W303. https://doi.org/10.1093/nar/gky427
Xu, F., Wang, H. J., Lin, Z. M., & Yu, B. (2015). Recurrent duplication mutation in HRAS causing mild Costello syndrome in a Chinese patient. Clinical and Experimental Dermatology, 40(4), 404-407. https://doi.org/10.1111/ced.12571
Zampino, G., Pantaleoni, F., Carta, C., Cobellis, G., Vasta, I., Neri, C., Pogna, E. A., De Feo, E., Delogu, A., Sarkozy, A., Atzeri, F., Selicorni, A., Rauen, K. A., Cytrynbaum, C. S., Weksberg, R., Dallapiccola, B., Ballabio, A., Gelb, B. D., Neri, G., & Tartaglia, M. (2007). Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. Human Mutation, 28(3), 265-272. https://doi.org/10.1002/humu.20431
Zenker, M., Lehmann, K., Schulz, A. L., Barth, H., Hansmann, D., Koenig, R., Korinthenberg, R., Kreiss-Nachtsheim, M., Meinecke, P., Morlot, S., Mundlos, S., Quante, A. S., Raskin, S., Schnabel, D., Wehner, L. E., Kratz, C. P., Horn, D., & Kutsche, K. (2007). Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. Journal of Medical Genetics, 44(2), 131-135. https://doi.org/10.1136/jmg.2006.046300